

1 **Immune evolution from preneoplasia to invasive lung adenocarcinomas and**  
2 **underlying molecular features**

3 Hitoshi Dejima<sup>1\*</sup>, Xin Hu<sup>2\*</sup>, Runzhe Chen<sup>3\*</sup>, Jiexin Zhang<sup>4\*</sup>, Junya Fujimoto<sup>1\*</sup>, Edwin R.  
4 Parra<sup>1</sup>, Cara Haymaker<sup>1</sup>, Shawna Hubert<sup>3</sup>, Dzifa Duose<sup>1</sup>, Solis Soto<sup>1</sup>, Dan Su<sup>5,6</sup>, Junya  
5 Fukuoka<sup>7</sup>, Hoa Pham<sup>7</sup>, Nicholas Mcgranahan<sup>8</sup>, Baili Zhang<sup>1</sup>, Lisha Ying<sup>5,9</sup>, Latasha Little<sup>2</sup>,  
6 Curtis Gumbs<sup>2</sup>, Chi-Wan Chow<sup>1</sup>, Marcos Roberto Estecio<sup>10,11</sup>, Myrna C.B. Godoy<sup>12</sup>, Mara  
7 B. Antonoff<sup>13</sup>, Boris Sepesi<sup>13</sup>, Harvey Pass<sup>14</sup>, Carmen Behrens<sup>3</sup>, Jianhua Zhang<sup>2</sup>, Ara A  
8 Vaporciyan<sup>13</sup>, John V. Heymach<sup>3</sup>, Paul Scheet<sup>15</sup>, J. Jack Lee<sup>16</sup>, P. Andrew Futreal<sup>2</sup>,  
9 Alexandre Reuben<sup>3#</sup>, Humam Kadara<sup>1#</sup>, Ignacio Wistuba<sup>1#</sup>, Jianjun Zhang<sup>2, 3#</sup>

10

11 **Affiliations**

12 Departments of <sup>1</sup>Translational Molecular Pathology, <sup>2</sup>Genomic Medicine, <sup>3</sup>Thoracic/Head  
13 and Neck Medical Oncology, <sup>4</sup>Bioinformatics & Computational Biology, <sup>10</sup>Epigenetics and  
14 Molecular Carcinogenesis, <sup>11</sup>Center of Cancer Epigenetics, <sup>12</sup>Thoracic Imaging,  
15 <sup>13</sup>Thoracic and Cardiovascular Surgery, <sup>15</sup>Epidemiology, <sup>16</sup>Biostatistics, The University of  
16 Texas MD Anderson Cancer Center, Houston, Texas, USA.

17 <sup>5</sup>Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,  
18 Hangzhou, China.

19 <sup>6</sup>Department of Pathology, <sup>9</sup>Zhejiang Cancer Research Institute, Cancer Hospital of the  
20 University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,  
21 China.

22 <sup>7</sup>Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences,  
23 Nagasaki, Japan.

24 <sup>8</sup>Cancer Research United Kingdom-University College London Lung Cancer Centre of  
25 Excellence, London, UK.

26 <sup>14</sup>Department of Cardiothoracic Surgery, New York University Langone Medical Center,  
27 New York, NY 10016, USA.

28 \* Co-first authors

29 # Correspondence should be addressed to Alexandre Reuben

30 ([AReuben@mdanderson.org](mailto:AReuben@mdanderson.org)), Humam Kadara ([HKadara@mdanderson.org](mailto:HKadara@mdanderson.org)), Ignacio  
31 Wistuba ([iwistuba@mdanderson.org](mailto:iwistuba@mdanderson.org)) or Jianjun Zhang ([jzhang20@mdanderson.org](mailto:jzhang20@mdanderson.org)).

32

### 33 **ABSTRACT**

34 The evolution of anti-tumor immune surveillance during initiation and progression of  
35 preneoplasia into invasive lung adenocarcinoma (ADC) and its underlying molecular  
36 changes are largely unknown. To fill this void, we characterized the immune contexture  
37 of invasive lung ADC (n=12) and its precursors of consecutive developmental stages  
38 including preneoplasia atypical adenomatous hyperplasia (AAH, n=22), adenocarcinoma  
39 *in situ* (AIS, n=16), minimally invasive adenocarcinoma (MIA, n=28) as well as paired  
40 normal lung tissues (NL, n=53) by transcriptomic profiling of 770 genes of nCounter  
41 PanCancer Immune Profiling Panel (Nanostring), T cell receptor (TCR) sequencing and  
42 multiplex immunofluorescence (mIF). Our results demonstrated that anti-tumor immunity  
43 evolved as a continuum from AAH to AIS, MIA and invasive lung ADC with a gradually  
44 less effective and more intensely regulated immune response evidenced by down-  
45 regulation of immune activation pathways, up-regulation of immunosuppressive pathways,

46 higher infiltration of CD4+ T cells, lower infiltration of CD8+ T cells, increased CD4/CD8  
47 ratio, decreased T cell clonality, lower frequencies of top T cell clones in later stages.  
48 Further correlation of these immune features with exome sequencing and methylation  
49 data demonstrated that the immune response could be impacted by oncogene mutation  
50 status, HLA loss, chromosomal copy number aberrations and DNA methylation  
51 aberrations suggesting that only cells in preneoplasia with the ideal combination of these  
52 molecular features enabling rapid proliferation and evasion from host immune could  
53 outgrow into the dominant clones in invasive lung ADCs. Importantly, the immune  
54 activation and evasion have started at preneoplastic stage advocating for immunotherapy  
55 in patients with lung ADC precursors for prevention of invasive lung cancers.

56

## 57 **INTRODUCTION**

58 Despite significant advances in its management, lung cancer remains the leading cause  
59 of cancer death worldwide (1, 2), largely due to late diagnosis at advanced stages when  
60 cures are generally unachievable (1, 3, 4). Computed tomography (CT) scan-guided lung  
61 cancer screening has demonstrated a reduction of lung cancer mortality by 26%-61% (5)  
62 highlighting the importance of early detection and intervention. These findings suggest  
63 that early cancer interception is crucial to reduce lung cancer incidence and mortality. Yet,  
64 to date, randomized clinical trials on primary lung cancer prevention have only produced  
65 disappointing results (5), primarily due to our rudimentary knowledge of early phases in  
66 lung cancer development. Improved understanding of targetable molecular mechanisms  
67 underlying early lung carcinogenesis may accelerate the development of precise  
68 diagnostic as well as effective preventive and therapeutic strategies.

69 Lung adenocarcinoma (ADC) is the most common histological subtype of lung cancer.  
70 Recent studies has postulated that lung ADC may arise from atypical adenomatous  
71 hyperplasia (AAH), the only recognized preneoplasia to lung ADC (6-12), which evolves  
72 into preinvasive adenocarcinoma *in situ* (AIS) (13), to micro-invasive lesion termed  
73 minimally invasive adenocarcinoma (MIA) (8, 14) and eventually frankly invasive ADC (8,  
74 14). Early-stage lung ADCs and their precursors usually present as lung nodules with  
75 distinct radiologic features called ground glass opacity (GGO). These lung nodules are  
76 often referred as indeterminate pulmonary nodules (IPN) without histologic diagnosis as  
77 the diagnostic yield from biopsy of GGO-predominate nodules is low and surgery is not  
78 the standard of care. This has subsequently led to the scarcity of appropriate materials to  
79 study the molecular profiles of lung ADC precursors (15).

80 Carcinogenesis results from progressive accumulation of molecular abnormalities  
81 (molecular evolution) (16) and escape from host immune surveillance (immunoediting)  
82 (17). Our recent gene expression and genomic pilot studies on lung ADC precursors have  
83 demonstrated distinct transcriptomic features (18) and progressive genomic evolution  
84 along the spectrum of AAH to AIS, MIA and ADC (19). However, the extent to which  
85 immunoediting sculpts early carcinogenesis of lung ADC and the underlying genomic  
86 and epigenetic alterations associated with these immune features still remain to be  
87 determined. In the current study, we performed immune gene expression profiling, T cell  
88 receptor (TCR) sequencing and multiplex immunofluorescence (mIF) staining on a cohort  
89 of resected AAH, AIS, MIA and invasive ADC lesions and paired morphologically normal  
90 lung tissues (NL) to delineate the evolution of immune contexture, particularly T cell  
91 landscape across different stages of early lung ADC pathogenesis. We further leveraged

92 whole exome sequencing (WES) (19) and methylation data from the same cohort of IPNs  
93 (Hu et al, bioRxiv, 2020) to underscore the genomic and epigenetic alterations that may  
94 impinge on these immune features (**Supplementary Table 1** and **Fig. 1**).

95

## 96 **RESULTS**

### 97 **Progressive decrease in overall immunity mirrors evolution from preneoplasia to** 98 **invasive lung adenocarcinoma**

99 To assess dynamic changes in the immune contexture during early lung carcinogenesis,  
100 we performed immune profiling using the nCounter PanCancer Immune Profiling Panel  
101 (NanoString), which includes 770 genes from 14 different immune cell types, common  
102 checkpoint inhibitors, cancer/testis antigens, and genes covering both the adaptive and  
103 innate immune response (20) on 47 resected pulmonary nodules (n=9 for AAH, n=11 for  
104 AIS, n=21 for MIA, and n=6 for invasive ADC) and 38 paired NL tissues. There were no  
105 differences in age (p=0.55, Kruskal test), sex (p=0.31, fisher exact test) or smoking status  
106 (p=0.35, fisher exact test) between patients with pulmonary nodules of different histologic  
107 stages. In total, 291 genes were differentially-expressed (DEGs) (**Supplementary Table**  
108 **2**). Interestingly, changes in the majority of DEGs, regardless of their direction, exhibited  
109 a progressive pattern along the spectrum from NL, AAH, AIS, MIA and up to ADC  
110 (**Supplementary Fig. 1**). Examples of progressively increased genes included immune  
111 suppressive genes *CD47* (protection of cancer cells from immune cell killing) (21), *CD276*  
112 (inhibition of immune responses) (22) and *CTLA4* (checkpoint molecule) (23), while  
113 progressively decreased genes included *ENTPD1* (expressed on tumor-specific T cells)

114 (24), granzyme B (*GZMB*) and perforin 1 (*PRF1*) (two cytotoxic molecules produced by T  
115 lymphocytes and natural killer cells (NK cells) (25, 26) (**Supplementary Fig. 2A-F**).  
116 These results suggest that immune evolution may have occurred in premalignant phases  
117 of lung carcinogenesis and progressed as a continuum from preneoplasia to invasive lung  
118 ADC with a gradually less effective and more intensely regulated immune response.  
119 Functional pathway analysis of DEGs revealed 26 significantly de-regulated pathways  
120 associated with neoplastic evolution from NL to invasive ADC, of which, 23 were down-  
121 regulated (**Fig. 2A**). All 3 up-regulated pathways, systemic lupus erythematosus (SLE) in  
122 B cell signaling, T cell exhaustion signaling and PARP signaling pathways could  
123 potentially impair immune response (27-29). Taken together, these results indicated an  
124 overall decreased immunity in later-stage lesions.

125 We next de-convoluted gene expression profiling data using TIMER (30) to evaluate  
126 changes in immune cell composition. As shown in **Fig. 2B**, CD4+ T lymphocyte infiltration  
127 progressively increased from NL to invasive ADC. Conversely, infiltration of CD8+ T  
128 lymphocytes progressively decreased with neoplastic evolution (**Fig. 2C**) leading to  
129 significantly higher CD4/CD8 ratio in later-stage lesions (**Fig. 2D**). Similarly, B cell  
130 infiltration (**Fig. 2E**) and tertiary lymphoid structure signatures progressively increased  
131 along the spectrum from NL to invasive ADC (**Supplementary Fig. 3**). To validate these  
132 findings, we applied TIMER to RNA sequencing data from an independent cohort  
133 previously published by our group and observed similar results (**Supplementary Fig. 4A-**  
134 **D**) (18). Further studies are warranted to understand the subtypes and functions of these  
135 B cells although concomitant upregulation of IL-10 (**Supplementary Fig. 5**) and SLE in

136 B cell signaling pathway (**Fig. 2A**) could indicate their negative impact on anti-tumor  
137 immunity in later-stage lesions.

138 To further evaluate changes in T cell subsets, we next compared gene expression of  
139 cytokines associated with Th1, Th2, Th17 and Treg differentiation and function (31, 32).  
140 Th1 cytokines were attenuated in AIS and MIA when compared with AAH and returned  
141 to baseline levels in ADC (**Supplementary Fig. 6**). Conversely, Th2 and Treg cytokines  
142 were overall higher in later stages (**Supplementary Fig. 6**), potentially suggesting helper  
143 T cell reprogramming to pro-tumor phenotypes along with neoplastic evolution.

144

#### 145 **Dynamic changes in T cell phenotype and infiltration define histologic stages of** 146 **early ADC development**

147 We next performed multiplex immunofluorescence (mIF) using antibodies against  
148 cytokeratin (CK), CD3, CD8, PD-1, PD-L1, CD68, CD45RO, GZMB and FoxP3 (**Fig. 3A**,  
149 **Supplementary Fig. 7** and **Supplementary Fig. 8**) on a subset of pulmonary nodules  
150 (n=9 for AAH, n=10 for AIS, n=21 for MIA, and n=6 for invasive ADC) and paired NL (n  
151 =7) to assess the dynamic changes of various subtypes of T cells and their interaction  
152 with (pre-)malignant cells during early lung carcinogenesis. Densities of infiltrating  
153 activated CTLs (CD3+CD8+GZMB+) and regulatory T cells (Treg, CD3+CD8-FoxP3+)  
154 assessed by mIF were positively correlated with corresponding CD8+ and CD4+ T cell  
155 infiltrate levels, derived from gene expression profiling, respectively (**Supplementary Fig.**  
156 **9A-B**). Furthermore, mIF-derived Treg/activated CTLs ratio closely recapitulated  
157 CD4/CD8 ratio from immune gene expression profiling (**Supplementary Fig. 9C**).

158 Correlations among immune subsets and between immune components and epithelial  
159 cells across IPNs of different histologic stages demonstrated that in normal tissues,  
160 densities of CK+ and CK+PD-L1+ cells were positively correlated, as were Tregs and  
161 memory T cells, cytotoxic and activated cytotoxic T cells (**Supplementary Fig. 10A**). For  
162 AAH, only total macrophages and activated cytotoxic T cells were positively correlated  
163 (**Fig. 3B**). In AIS, PD-L1+ macrophages were positively correlated with Tregs, antigen-  
164 experienced T cells and cytotoxic T cells (**Fig. 3C**). For MIA, CK cells were negatively  
165 correlated with total macrophages and memory T cells, while Tregs were positively  
166 correlated with antigen-experienced T cells and memory T cells were correlated with  
167 cytotoxic and activated cytotoxic T cells (**Fig. 3D**). Finally, in ADC, PD-L1+CK+ cells were  
168 correlated with total and PD-L1+ macrophages, PD-L1+ macrophages were correlated  
169 with total macrophages, and Tregs were correlated with memory T cells (**Supplementary**  
170 **Fig. 10B**). Overall, relationships between cell types varied widely across stages,  
171 highlighting the dynamic nature of tumor-immune interactions during tumor evolution.

172

### 173 **Progressively divergent TCR repertoire with neoplastic progression**

174 Because of the central role of T cells in tumor surveillance, we next sought to investigate  
175 the T cell repertoire (33) by multiregional T cell receptor (TCR) sequencing on 158  
176 spatially-separated specimens from 13 AAH, 11 AIS, 23 MIA and 10 ADC as well as 49  
177 NL. We first assessed the T cell diversity using Inverse Simpson Index (34). T cell  
178 diversity was positively correlated with infiltration of CD4+ T cells derived from gene  
179 expression profiling (**Supplementary Fig. 11A**) as well as densities of Tregs from mIF  
180 (**Supplementary Fig. 11B**) and increased steadily from AAH to AIS, MIA and ADC



181 ( $p < 0.0001$ ) (**Fig. 4A**) in line with higher CD4+ T cells in later stage lesions (**Fig. 2B**). We  
182 then compared distributions of T cell clones across histologic stages, focusing on the  
183 most expanded T cell clones (35, 36). As shown in **Fig. 4B** and **Supplementary Fig. 12**,  
184 the top 10, 100, 200, and 500 clones accounted for a higher frequency in the NLs, and  
185 gradually decreased in AAH, AIS, MIA and invasive ADC ( $p < 0.0001$ ) implying suppressed  
186 T cell expansion during early carcinogenesis of lung ADC.

187

### 188 **Suppression of T cell repertoire may occur at the preneoplastic stage**

189 To further understand the T cell response at different histologic stages, we calculated T  
190 cell clonality, a metric indicating expansion and activation of T cell clones. T cell clonality  
191 was positively correlated with infiltration of CD8+ T cells ( $r = 0.561$ ,  $p = 4.863e-06$ ),  
192 activated CTLs ( $r = 0.318$ ,  $p = 7.340e-03$ ), *GZMB* expression ( $r = 0.319$ ,  $p = 5.068e-02$ ) and  
193 Th1 cytokines ( $r = 0.473$ ,  $p = 3.923e-05$ ) (**Supplementary Fig. 13A-D**), while negatively  
194 correlated with infiltration of CD4+ T cells ( $r = -0.385$ ,  $p = 8.993e-04$ ) and Tregs ( $r = -0.477$ ,  
195  $p = 2.965e-05$ ) (**Supplementary Fig. 13E-F**) suggesting that T cell clonality was mainly  
196 driven by clonal expansion of activated CTLs, with Tregs inhibiting CTL responses.  
197 Comparing T cell clonality among different stages revealed the highest clonality in NL  
198 (**Fig. 4C**) consistent with our previous findings (25). Clonality declined from NL to AAH  
199 increasing in AIS/MIA and declining to its lowest level in ADC (**Fig. 4C**). These results  
200 suggest that early ADC pathogenesis is associated with local immunosuppression that  
201 may have commenced at the preneoplastic stage.

202

## 203 **Driver mutations affect the immune response in pre/early ADC**

204 We next sought to explore the molecular features associated with the immune contexture  
205 observed in these lesions. We first probed the two most frequently mutated driver genes  
206 in this cohort *EGFR* and *KRAS* (19). Compared to *EGFR*-mutant lesions or double wild-  
207 type lesions, *KRAS*-mutant lesions exhibited highest CD8+ T cell infiltration and lowest  
208 CD4+/CD8+ T cell ratio inferred from immune gene expression; highest CTL infiltration,  
209 highest effector memory cytotoxic T cell infiltration, highest CTL/Treg ratio from mIF as  
210 well as highest T cell clonality from TCR sequencing (**Supplementary Fig. 14A-F**). These  
211 trends remained similar when analyzing each histologic stage (**Supplementary Fig. 15A-**  
212 **F**). These findings are consistent with our previous studies in invasive lung cancers (37)  
213 and emphasize the interplay between oncogene mutations and immune surveillance  
214 during early pathogenesis of lung adenocarcinoma.

215

## 216 **Chromosomal copy number variations and HLA loss may contribute to impaired T** 217 **cell responses**

218 In light of recent studies suggesting immune evasion could be facilitated by an inability to  
219 present neoantigens due to loss of HLA (26), we applied the LOHHLA (loss of  
220 heterozygosity in HLA) algorithm (38) to WES data from these lesions (19). LOH at the  
221 HLA loci was observed in 7%, 15% and 33% of AIS, MIA and ADC respectively, but in  
222 none of AAH lesions (**Supplementary Fig. 16A**,  $p=0.005$ , Chi-Square test). Correlation  
223 with T cell infiltration derived from immune gene expression profiling demonstrated that

224 lesions with HLA LOH had similar CD4+ T cell infiltration, but trends of lower CD8+ T cell  
225 infiltration and higher CD4/CD8 ratio (**Supplementary Fig. 16B-D**).

226 Chromosomal copy number variation (CNV) has been reported to impact immune  
227 microenvironment across different cancers (39). We next investigated whether CNV  
228 affected the immune landscape of these lung ADC precursors. Correlation with T cell  
229 infiltration derived from gene expression profiling demonstrated allelic imbalance (AI), a  
230 subtle form of CNV, was negatively correlated with CD8+ T cell infiltration, but positively  
231 correlated with CD4+ T cell infiltration and CD4+/CD8+ T cell ratio (**Supplementary Fig.**  
232 **17A-C**). Similar trend was also observed with CNV burden, although these differences  
233 did not reach statistical significance (**Supplementary Fig. 17D-F**). Interestingly, HLA-  
234 LOH positive lesions exhibited significantly higher AI burden and CNV burden compared  
235 to that of HLA-LOH negative lesions (**Supplementary Fig. 18A-B**). One plausible  
236 explanation is that the development AI, CNV or HLA LOH resulted from chromosomal  
237 instability (CIN) and cell clones with CIN may lead to higher CNV/AI burdens as well as  
238 increased likelihood of HLA loss, which could subsequently enable these cells escaping  
239 from anti-tumor immune surveillance and developing into dominant clones in the later  
240 stage neoplastic lesions.

241

## 242 **Methylation status interacts with genomic alterations and impacts the immune** 243 **response during early lung cancer pathogenesis**

244 Somatic mutations play central roles in activating anti-tumor immune responses through  
245 generating neoantigens that can be recognized by T cells (40, 41). As shown in  
246 **Supplementary Fig. 19A-B**, a progressive increase in both MHC-I or MHC-II associated

247 predicted neoantigens was observed from AAH to AIS, MIA and ADC. However, analysis  
248 of methylation data from reduced representation bisulfite sequencing (RRBS) of the same  
249 cohort of IPNs (Hu et al, bioRxiv, 2020) revealed that a significantly larger proportion of  
250 genes associated with predicted neoantigens exhibited promoter hypermethylation (>30%  
251 CpG methylated) in later-stage lesions, thus potentially dampening expression of  
252 neoantigens in later stage lesions (**Supplementary Fig. 19C-D**). These data suggest that  
253 promoter hypermethylation could contribute to neoantigen depletion and immune escape.  
254 Furthermore, we assessed the impact of global methylation status, using long  
255 interspersed transposable elements-1 (LINE-1) as a surrogate marker (42-44), on the  
256 immune microenvironment in these lesions. Overall, global methylation level was  
257 negatively associated with CD4+ T cell infiltration and CD4/CD8 ratio derived from gene  
258 expression profiling, Tregs infiltration and Treg/CD8 ratio from mIF (**Supplementary Fig.**  
259 **20A-D**) suggesting decreased global methylation was associated suppressive immune  
260 contexture.

261

## 262 **DISCUSSION**

263 Cancer evolution is shaped by the interaction between cancer cells and host immune  
264 surveillance, a process termed immunoediting consisting of elimination, equilibrium, and  
265 escape phases (45-47). It is well documented that the majority of human cancers are  
266 infiltrated with various immune cells, but often in an immunosuppressive  
267 microenvironment as remnant evidence of immunoediting (48, 49). The T cell immunity is  
268 significantly compromised even in stage I lung cancers (37, 50) indicating that these  
269 cancers have already begun evading the anti-tumor immune surveillance. However, when

270 and how the elimination and equilibrium phases occur over the lung cancer evolution  
271 continuum is unknown. Therefore, investigating the molecular and immune landscape of  
272 lung premalignancies is warranted to elucidate the timing of immune activation/evasion  
273 and its underlying molecular mechanisms during early lung carcinogenesis.

274 In the current study, we leveraged a relatively large cohort of resected lung ADC  
275 precursors with available genomic and epigenetic profiling data to characterize the  
276 dynamic changes in the immune contexture across different consecutive developmental  
277 stages by gene expression profiling, mIF and TCR sequencing. To the best of our  
278 knowledge, this is the first systemic and comprehensive study on immune evolution  
279 during early carcinogenesis of lung ADC and its potential underlying molecular basis.  
280 Overall, there was a more suppressive and tightly controlled immune response,  
281 particularly T cell response, in later stage lesions highlighting that the dynamic  
282 interaction between cancer cells and host immune surveillance was overall evolving  
283 toward immune escape along with pathogenesis of lung ADC. Notably, dynamic  
284 changes in immune contexture progressed as a continuum from preneoplasia AAH to  
285 pre-invasive AIS, to micro-invasive MIA and finally frankly invasive ADC without obvious  
286 “step-wise” major leaps at transitions between different histologic stages. This is  
287 consistent with the overall progressive genomic evolution from AAH to AIS, MIA and ADC  
288 (19) suggesting that early carcinogenesis of lung ADC is a gradual process shaped by  
289 continuous interaction with host immune surveillance. Importantly, dynamic immune  
290 activation and suppression have already started at preneoplastic stage. This is in line  
291 with a similar study on lung squamous cell carcinoma (SCC) precursors by Mascaux and  
292 colleagues, which revealed evidence of both immune activation and evasion along with

293 evolution of preinvasive SCC lesions (51). Taken together, these data advocate for  
294 therapy targeting the immune microenvironment in patients with lung cancer precursors  
295 to prevent development of invasive lung cancers.

296 Identification of the molecular basis underlying immune activation and evasion may  
297 provide novel insights for understanding tumor-immune interactions and establishing  
298 biomarkers to select patients who may benefit from immunoprevention. WES (19) and  
299 RRBS data (Hu, et al BioRxiv, 2020) available from the same cohort of pulmonary nodules  
300 provided the opportunity to depict the genomic and epigenetic features associated with  
301 the distinct immune landscape. Overall, oncogene mutations, HLA loss, CNV burden, AI  
302 burden and methylation status were all found to associate with the immune contexture,  
303 similarly to advanced cancers (52, 53). For example, *KRAS* mutations correlated with  
304 more active immune response, while *EGFR* mutations, HLA loss, higher CNV burden and  
305 decreased global methylation status correlated with a cold immune microenvironment.  
306 However, associations with any single genomic or epigenetic feature were weak,  
307 suggesting heterogenous but convergent evolution towards immune escape during early  
308 lung carcinogenesis.

309 Our previous work suggested that early lung ADC carcinogenesis may predominantly  
310 follow the clonal sweep model, whereby certain subclones in early-stage preneoplasia  
311 turn into dominant clones in later-stage diseases while unfit subclones are eliminated(19),  
312 primarily by the host immune system. In the early phases of carcinogenesis, the  
313 stochastic genomic and epigenetic alterations lead to heterogeneous subclones with  
314 various combinations of molecular features that define the distinct biology of each  
315 subclone including survival ability under selective immune pressure. The impact of

316 genomic and epigenetic alterations on immune response is intertwined. For example,  
317 methylation may directly affect immune response by regulating expression of immune  
318 genes (54) or potential neoantigens (55) or indirectly by increasing DNA vulnerability for  
319 development of CNV and somatic mutations that can subsequently influence the immune  
320 microenvironment (56, 57). Global hypomethylation is known to associate with CIN (58)  
321 and increased rate of somatic mutations (59) and indeed, global methylation level was  
322 negatively associated with TMB and CNV burden in this cohort of lesions (Hu, et al  
323 BioRxiv, 2020). Since high CNV burden is associated with a cold immune  
324 microenvironment (39) while high TMB can increase tumor immunogenicity and facilitate  
325 immune recognition and elimination of cancer cells (60), the impact of global  
326 hypomethylation (associated with both high CNV burden and TMB) on anti-cancer  
327 immunity is further complicated. In the end, the outgrowth of the subclones is determined  
328 by the accumulated effects of all molecular aberrations. Only the cells with the ideal  
329 combination of molecular features enabling their rapid proliferation and escape from  
330 immune attack will survive and outgrow into the dominant clones in invasive cancers. For  
331 example, though invasive lung ADCs tend to harbor a high predicted neoantigen burden  
332 that could lead to more active anti-tumor immune response, they also exhibited a higher  
333 CNV burden, higher likelihood of losing HLA and decreased global methylation, all of  
334 which are associated with a cold tumor immune microenvironment (61-64), resulting in  
335 an overall cold immune microenvironment in invasive ADCs (lower CD8+ T cell infiltration,  
336 lower CTL, lower T cell clonality, higher CD4+ T cell infiltration and higher Tregs).

337 With the increasing implementation of CT-guided screening and advent of high-resolution  
338 diagnostic CT scans, there has been a drastic increase in the detection of IPNs (65, 66),

339 many of which are lung ADC precursors. However, the management remains  
340 controversial. Although surgical resection could potentially offer cure in a large proportion  
341 of these patients, surgery-associated morbidity and high cost have called surgical  
342 resection into question. Additionally, ~25% patients often present with multifocal diseases,  
343 which complicates surgery. We have previously demonstrated (18, 19) that preinvasive  
344 lung ADC precursors were molecularly simpler, and therefore theoretically easier to  
345 eradicate. In the current study, we showed that lung ADC precursors may exhibit an  
346 overall better-preserved anti-tumor immune landscape. In light of these findings,  
347 therapeutic strategies reprogramming the tumor immune microenvironment in patients with  
348 lung ADC precursors prior to further immunosuppression in invasive lung cancers may  
349 be beneficial. The lung cancer immunoprevention clinical trial IMPRINT-Lung  
350 ([NCT03634241](https://clinicaltrials.gov/ct2/show/study/NCT03634241)) recruiting individuals with high-risk IPNs is currently underway to validate  
351 this hypothesis.

352

## 353 **METHODS**

### 354 **Patients and tissue processing**

355 Specimens were collected from 53 patients presenting with pulmonary nodules, who  
356 underwent surgical resection at Nagasaki Hospital (Japan) or Zhejiang Cancer Hospital  
357 (China) from 2014 to 2017 as described previously (19). The study was approved by the  
358 Institutional Review Boards (IRB) at MD Anderson Cancer Center, Nagasaki University  
359 Graduate School of Biomedical Sciences and Zhejiang Cancer Hospital. Hematoxylin and



360 eosin (HE) slides of each case were reviewed by experienced lung cancer pathologists  
361 to confirm the diagnosis before further analyses.

### 362 **DNA and RNA extraction**

363 After pathologic assessment, manual macro-dissection was performed to enrich  
364 premalignant cells or cancer cells for DNA or RNA extraction. DNA or RNA was isolated  
365 using the AllPrep® DNA/RNA FFPE Kit (Qiagen, Hilden, Germany) according to  
366 manufacturer's instructions. Finally, the DNA samples were quantified by NanoDrop 1000  
367 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and RNA was quantified  
368 using the RNA High sensitivity kit on the Qubit 3.0 fluorometer (Thermo Fisher Scientific,  
369 USA). RNA quality and integrity were evaluated with RNA integrity number (RIN) (67),  
370 concentration (ng/μl), and size (nt) using RNA Screen Tape in 4200 Tape Station System  
371 (Agilent Technologies, USA).

### 372 **Gene profiling of immune cells using nCounter® platform**

373 The nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc.,  
374 Seattle, WA, USA), which contains 770 genes (including 730 immune associated genes  
375 and 40 housekeeping genes) using NanoString nCounter Analysis was applied for gene  
376 expression profiling as previously described (68, 69). The data were imported into the  
377 nSolver 4.0 software (NanoString Technologies) for quality control (QC). After the QC  
378 was performed with default setting, background correction was done with negative  
379 controls, and data was normalized by using the geometric mean of the 6 positive controls,  
380 and 40 housekeeping genes. We further performed quantile-normalization and log<sub>2</sub>  
381 transformation to stabilize the variance. A one-way ANOVA test was applied to identify

382 differentially expressed genes (DEGs) in different stages. We modeled the p-values using  
383 a beta-uniform mixture (BUM) model, combined with false discovery rate (FDR) to  
384 determine a cutoff for p-values (70). The DEGs, along with log ratios were then evaluated  
385 with Ingenuity Pathway Analysis (IPA) software (Quiagen, Hilden, Germany) (71) to  
386 identify pathways that are enriched by these DEGs. We performed a Core Analysis with  
387 species set to human and tissue set to lung. IPA identifies the top canonical pathways  
388 associated with the list of DEGs by the Fisher's exact test to ascertain enrichment. IPA  
389 also calculates a z-score to predict activation status of the pathway by comparing input  
390 genes and the stored activity pattern.

### 391 **Multiplex immunofluorescence staining**

392 All samples were confirmed to be appropriate for multiplex immunofluorescence (mIF)  
393 analysis based on tissue quality and availability using the HE staining of same lesion by  
394 the experienced pathologist. The manual mIF staining was performed on unstained slides  
395 of FFPE samples using the Opal 7-Color IHC Kit (Akoya Biosciences, USA) as previously  
396 described (72). Eight immune markers were placed in two 6-antibody panels before the  
397 stained slides were scanned by Vectra multispectral microscope (Akoya Biosciences,  
398 USA). Panel 1 contained pancytokeratin (AE1/AE3; epithelial marker; dilution 1:300; Dako,  
399 Carpinteria, CA), PD-L1 (clone E1L3N, dilution 1:100; Cell Signaling Technology, Beverly,  
400 MA), PD1 (clone EPR4877-2, dilution 1:250; Abcam, Cambridge, MA), CD3 (T  
401 lymphocyte marker; dilution 1:100; Dako), CD8 (cytotoxic T cell marker; clone C8/144B,  
402 dilution 1:20; Thermo Fisher Scientific, Waltham, MA), and CD68 (macrophage marker;  
403 clone PG-M1, dilution 1:450; Dako). Panel 2 contained pancytokeratin, CD3, CD8,  
404 CD45RO (memory T cell marker; clone UCHL1, ready to use; Leica Biosystems, Buffalo

405 Grove, IL), Granzyme B (cytotoxic lymphocyte marker; clone F1, ready to use; Leica  
406 Biosystems), and FoxP3 (regulatory T cell marker; clone 206D, dilution 1:50; BioLegend,  
407 SanDiego, CA). Human tonsil FFPE tissues were used with each individual antibody on  
408 same fluorochrome assay to build the spectral library, and were also used with and  
409 without primary antibodies as positive and negative (autofluorescence) controls,  
410 respectively. The stained slides were scanned with Vectra 3.0 multispectral microscope  
411 system (Akoya Biosciences, USA) under fluorescent illumination. These mIF assays  
412 followed our previous publication (73).

### 413 **Multispectral analysis**

414 The five individual fields for multispectral analysis were selected from areas of interest in  
415 a scanned low magnification ( $\times 10$ ) image on Phenochart1.0.9 (Akoya Biosciences, USA).  
416 The five high magnification ( $\times 20$ ) fields for mIF analysis were carefully selected by  
417 experienced pathologists after comparing with HE slides to capture malignant and  
418 premalignant cell cluster and various elements of heterogeneity. The corresponding  
419 normal fields were selected in the farthest field of tumor periphery with morphological  
420 normal tissue on the same slide (**Supplementary Fig. 7A**). The selected high  
421 magnification field was total  $1.6725 \text{ mm}^2$  in size ( $669 \times 500 \mu\text{m}$  per field) (**Supplementary**  
422 **Fig. 7B**). Each field with panel 1 and panel 2 were overlapped with sequential sections.  
423 The target areas were analyzed by in Form 2.4.4 software (Akoya Biosciences, USA).  
424 The area was divided into two compartments: the epithelial compartment (the alveolar  
425 wall and septal or malignant cell nests) and alveolar air space or tumor stroma  
426 compartment (**Supplementary Fig. 7C**). The individual cells were recognized by DAPI  
427 nuclei staining (**Supplementary Fig. 7D**). Panel 1 contained the co-localization patterns

428 as follows: PD-L1 expressing CK+ cells (CK+PD-L1+), total T lymphocytes (total CD3+),  
429 cytotoxic T lymphocytes (CD3+CD8+), antigen experienced T lymphocytes (CD3+PD-1),  
430 antigen experienced cytotoxic T lymphocytes (CD3+CD8+PD-1+), total macrophages  
431 (total CD68+), and PD-L1 expressing macrophages (CD68+ PD-L1+). Panel 2 contained  
432 the co-localization patterns as follows: total T lymphocytes (total CD3+), cytotoxic T  
433 lymphocytes (CD3+CD8+), activated cytotoxic T lymphocytes (CD3+CD8+GB+), memory  
434 T lymphocytes (CD3+CD45RO+), effector/memory T lymphocytes  
435 (CD3+CD8+CD45RO+), regulatory T lymphocytes (CD3+FOXP3+CD8-), and  
436 memory/regulatory T lymphocytes (CD3+CD45RO+FOXP3+) (**Supplementary Fig. 8**).  
437 The percentage of the total nucleated cell density from each individual cell phenotyping  
438 population was used for further analysis.

### 439 **TCR $\beta$ amplification and sequencing**

440 Immunosequencing of the CDR3 regions of human TCR $\beta$  chains was performed using  
441 the protocol of ImmunoSeq (Adaptive Biotechnologies, hsTCR $\beta$  Kit) and T cell clonality  
442 and diversity were calculated as described previously (37, 74).

443 Briefly, T cell clonality is a metric of T cell proliferation and reactivity, and it is defined as  
444 1-Pielou's evenness and is calculated on productive rearrangements by:

$$1 + \frac{\sum_i^N p_i \log_2(p_i)}{\log_2(N)}$$

445

446 Where  $p_i$  is the proportional abundance of rearrangement  $i$ , and  $N$  is the total number of  
447 rearrangements. Clonality ranges from 0 to 1: values approaching 0 indicate a very even

448 distribution frequency of different clones (polyclonal), whereas values approaching 1  
449 indicate a distinct asymmetric distribution in which a few activated clones are present at  
450 high frequencies (monoclonal).

451 We also applied Inverse Simpson in order to observe T cell diversity, the sum over all  
452 observed rearrangements of the square fractional abundances of each rearrangements  
453 using productive templates.

$$\frac{1}{\sum_{i=1}^S p_i^2}$$

456 Where  $p_i$  is the proportional abundance of rearrangement  $i$ , and  $S$  is the total number of  
457 rearrangements. Inverse Simpson ranges from 1 to infinite, where a sample with little  
458 variation or abundance has a value approaching 1, and a maximally diverse and evenly  
459 distributed sample has a value approaching infinite.

#### 460 **Analysis of genomic and methylation profiling data**

461 Genomic and methylation data were generated and processed in previous studies as  
462 described (19) (Hu, et al, Bioxiv, 2020). Somatic mutations, allelic imbalance (AI), copy  
463 number variations (CNV), oncogene mutations, global methylation data were directed  
464 from above mentioned studies. The following additional analyses were performed on the  
465 genomic data.

#### 466 **Detection of allele-specific HLA loss**

467 Class I HLA alleles for each HLA gene was inferred by POLYSOLVER using a two-step  
468 Bayesian classification approach (75). This approach takes into account the base

469 qualities of aligned reads, observed insert sizes, as well as the ethnicity-dependent prior  
470 probabilities of each allele (75). Tumor purity and ploidy were estimated using ASCAT  
471 (76). We then applied LOHHLA (Loss Of Heterozygosity in Human Leukocyte Antigen)  
472 algorithm (38) to detect allele-specific HLA loss in each sample. In brief, logR and BAF  
473 across each HLA gene loci was obtained by binning the coverage at mismatch positions  
474 between homologous HLA alleles, and HLA haplotype specific copy numbers were then  
475 calculated based on logR and BAF value from the corresponding bin adjusted by tumor  
476 purity and ploidy. The median value of binned allelic copy number was used to determined  
477 LOH, where a copy number of  $< 0.5$  indicated allele loss and AI was determined if  $p <$   
478 0.01.

#### 479 **Prediction of neoantigens**

480 All peptides with 9-12 amino acids that span missense or stop gain mutations were  
481 extracted as mutant peptides to identify candidate peptides binding to MHC Class I or II  
482 molecules. The affinity of 9-12 peptides binding to MHC Class I molecules were predicted  
483 using the NetMHCpan3.0 binding algorithm (77). The affinity of 9-12 mer peptides binding  
484 to MHC Class II molecules were predicted using the NetMHCIIpan3.1 binding algorithm  
485 (78). The threshold for strong binding peptides is defined as half-maximum inhibitory  
486 concentration (IC<sub>50</sub>) affinity value  $< 50$  nM or a rank percentage score  $< 0.5\%$ ; the  
487 threshold for weak binding peptides is defined as IC<sub>50</sub>  $< 500$  nM or a rank percentage  
488 score  $< 2\%$ . HLA-A, HLA-B, HLA-C are included in MHC class I molecules, and HLA-DR,  
489 HLA-DP and HLA-DQ are included in MHC Class II molecules.

#### 490 **Statistical Analysis**

491 Different statistical models were applied to assess the association among immune data,  
492 genomic data and methylation data. When assessing association between two variables,  
493 different tests were applied depending on the types of variables. For association between  
494 two continuous variables, spearman's rank correlation test was used. For association  
495 between one continuous variable and one categorical variable, Wilcoxon rank-sum test  
496 (categorical variable with two levels) and Kruskal-Wallis test (categorical variable with  
497 more than two levels) were applied. The FDR method was used for multiple testing  
498 adjustment of p-values(79). All p-values are calculated with two-sided test, and  $p < 0.05$   
499 was considered to be statistically significant.

500

## 501 **DATA AVAILABILITY**

502 The data from WES has been deposited at European Genome-phenome Archive (EGA),  
503 which is hosted by The European Bioinformatics Institute (EBI) and the Centre for  
504 Genomic Regulation (CRG) under the accession code: EGAS00001004960  
505 [<https://www.ebi.ac.uk/ega/datasets/EGAD00001004960>]. All other data may be found  
506 within the main manuscript or supplementary Information or available from the authors  
507 upon request.

508

## 509 **COMPETING INTERESTS**

510 Dr. Zhang reports research funding from Merck, Johnson and Johnson, and consultant  
511 fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent  
512 outside the submitted work. The other authors declare no competing financial interests.

513

514 **ACKNOWLEDGMENTS**

515 This study was supported by the MD Anderson Khalifa Scholar Award, the National  
516 Cancer Institute of the National Institute of Health Research Project Grant  
517 (R01CA234629-01), the AACR-Johnson & Johnson Lung Cancer Innovation Science  
518 Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program, the MD  
519 Anderson Lung Cancer Moon Shot Program, Sabin Family Foundation Award, Duncan  
520 Family Institute Cancer Prevention Research Seed Funding Program, the Cancer  
521 Prevention and Research Institute of Texas Multi-Investigator Research Award grant  
522 (RP160668) and the UT Lung Specialized Programs of Research Excellence Grant  
523 (P50CA70907).



524 **FIGURE LEGEND**

525 **Figure 1. The immune evolution from preneoplasia to invasive lung**  
526 **adenocarcinoma and associated genomic and epigenomic features.** Infiltration of B  
527 cells, CD4+ T cells, CD8+ T cells inferred from immune gene expression using TIMER;  
528 regulatory T cells (Treg) and activated cytotoxic T lymphocytes (CTL) measured by  
529 multiplex immunofluorescence (mIF); T cell clonality and frequency of the top 100 T cell  
530 clones by TCR sequencing are shown in upper panel. Genomic alterations from whole  
531 exome sequencing (WES) including *EGFR/KRAS* mutations, HLA loss, copy number  
532 variation (CNV) burden, allelic imbalance (AI) burden, total number of mutations  
533 associated with predicted neoantigens, total number of mutations associated with  
534 predicted neoantigens without promoter methylation; global methylation status accessed  
535 by reduced representation bisulfite sequencing (RRBS) are shown in bottom panel. AAH:  
536 typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive  
537 adenocarcinoma. ADC: invasive adenocarcinoma.

538 **Figure 2. Progressively changes of immune cell infiltrations from preneoplasia to**  
539 **invasive lung adenocarcinoma. (A)** Significantly enriched functional pathways based  
540 on the 291 differentially expressed genes by Ingenuity pathway analysis (IPA®; Ingenuity  
541 Systems) software. Pathways with  $-\log(p\text{-value}) > 10$  (p-values are obtained from  
542 Fisher's right-tailed exact test) and an absolute z-score  $> 0.5$  are shown. Pathways that  
543 were predicted to be inhibited (negative Z scores) in later stages are in blue and pathways  
544 that were predicted to be activated (positive Z scores) in later stages are in orange. The  
545 heights of the bars indicate the significance of the enrichment ( $-\log(p\text{-value})$ ) and the  
546 scales of the orange or blue colors represent the predicted directionality. Fractions of

547 immune cells including CD4+ T cells (**B**), CD8+ T cells (**C**), CD4/CD8 ratio (**D**) and B cells  
548 (**E**) were estimated using TIMER based on the gene expression using nCounter  
549 PanCancer Immune Profiling Panel. Error bars indicate 95% confidence intervals and  
550 solid point represent mean value in each stage. The difference of cell fraction among  
551 different stages was evaluated using the Kruskal-Wallis H test. NL: Normal lung tissue,  
552 AAH: Atypical adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally  
553 invasive adenocarcinoma, ADC: Invasive adenocarcinoma.

554 **Figure 3. Dynamic changes of various immune cells and their interaction with**  
555 **epithelial cells across preneoplasia to invasive lung adenocarcinoma. (A)**  
556 Representative multiplex immunofluorescence (mIF) images each histologic stage  
557 analyzed by panel 1 and panel 2 markers. The correlation between immune cell subtypes  
558 and CK+ epithelial cells measured by mIF in AAH (**B**), AIS (**C**) and MIA (**D**). Significant  
559 correlation was marked with \* ( $p < 0.05$ ). Red circles indicate positive correlations and blue  
560 circles indicate negative correlations. The size of circles is proportional to the spearman's  
561 correlation co-efficient between each pair of cells. AAH: Atypical adenomatous  
562 hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive adenocarcinoma.

563 **Figure 4. Dynamic change in T cell repertoire from preneoplasia to invasive lung**  
564 **adenocarcinoma. T cell diversity (A) and T cell clonality (C) in normal lung, AAH, AIS,**  
565 **MIA and invasive ADC. (B) Distribution of T cell clones with frequency of top 1 (brown),**  
566 **top 2 to 10 (black), top 11 to 100 (orange), top 101 to 200 (purple), top 201 to 500 (green),**  
567 **top 501 to 1000 (red) and beyond 1000 (blue) in normal lung, AAH, AIS, MIA and invasive**  
568 **ADC lesions.**

569 **Supplementary Figure 1. The dynamic changes in differentially expressed genes**  
570 **from preneoplasia to invasive lung adenocarcinoma.** Gene expression profiling was  
571 performed using the nCounter PanCancer Immune Profiling Panel. The 291 differentially  
572 expressed genes (DEG) were identified with one-way ANOVA ( $FDR < 0.1\%$ ). Vertical  
573 scale corresponds to log ratio between means of ADC and N samples. Red: down-  
574 regulated genes in later stages. Green: up-regulated in later stages. N: normal lung  
575 tissues. AAH: typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA:  
576 minimally invasive adenocarcinoma. ADC: invasive adenocarcinoma.

577 **Supplementary Figure 2. Example genes differentially expressed from**  
578 **preneoplasia to invasive lung adenocarcinoma.** *CD47* (A), *CD276* (B), *CTLA4* (C),  
579 *ENTPD1* (D), *GZMB* (E), *PRF1* (F). The difference in expression of each gene among  
580 different stages was evaluated using the Kruskal-Wallis H test. AAH: typical adenomatous  
581 hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive adenocarcinoma. ADC:  
582 invasive adenocarcinoma.

583 **Supplementary Figure 3. Expression of tertiary lymphoid structure (TLS) signature**  
584 **genes from preneoplasia to invasive lung adenocarcinoma.** (A) Gene expression  
585 profiling was performed using the nCounter PanCancer Immune Profiling Panel  
586 (Nanostring). Principal component analysis was performed to 12 TLS signature  
587 chemokines (*CCL2*, *CCL3*, *CCL4*, *CCL5*, *CCL8*, *CCL18*, *CCL19*, *CCL21*, *CXCL9*,  
588 *CXCL10*, *CXCL11*, and *CXCL13*) and the PC1/PC2, representing the most variability  
589 across all samples, was used to derive the 12-chemokine TLS signature score. The  
590 difference of 12-chemokine TLS signature score among different stages was evaluated  
591 using the Kruskal-Wallis H test. (B) The correlation between 12 chemokine TLS signature

592 score and B cell infiltration. B cell infiltration was derived from gene expression profiling  
593 using TIMER. The correction coefficient ( $\rho$ ) was assessed by Spearman's rank  
594 correlation test.

595 **Supplementary Figure 4. Progressively changes of immune cell in filtration normal**  
596 **lung, preneoplasia and invasive lung adenocarcinoma.** Immune cell fractions  
597 including CD4+ T cells (**A**), CD8+ T cells (**B**), CD4 /CD8 ratio (**C**), B cells (**D**) were  
598 estimated using TIMER based on previously published RNA sequencing data from an  
599 independent cohort (GSE102511). Error bars indicate 95% confidence intervals and solid  
600 point represent mean value in each stage. The difference of cell fraction among stages  
601 was evaluated using the Kruskal-Wallis H test. NL: Normal lung tissue, AAH: Atypical  
602 adenomatous hyperplasia, ADC: Invasive adenocarcinoma.

603 **Supplementary Figure 5. Expression of IL-10 from AAH to ADC.** Gene expression  
604 profiling was performed using the nCounter PanCancer Immune Profiling Panel  
605 (Nanostring). The difference of expression among different stages was evaluated using  
606 the Kruskal-Wallis H test.

607 **Supplementary Figure 6. The dynamic changes of cytokines relevant to different**  
608 **helper T cells (Th) and regulatory T cells (Tregs).** (**A**) The heatmap represent  
609 expression of cytokines relevant to Th1, Th2, Th17 and Tregs in different stages. (**B**) The  
610 average expression of marker cytokines relevant to Th1, Th2, Th17 and Tregs in each  
611 stage. NL: Normal lung tissue, AAH: Atypical adenomatous hyperplasia, AIS:  
612 Adenocarcinoma in situ, MIA: Minimally invasive adenocarcinoma, ADC: Invasive  
613 adenocarcinoma.

614 **Supplementary Figure 7. Quantitative image analysis of multiplex**  
615 **immunofluorescence image data.** (A) After immunofluorescent staining, high  
616 magnification fields of interest were selected in both malignant (pre-malignant) and non-  
617 malignant regions. The non-malignant fields at the farthest regions from malignant  
618 (pre-malignant) regions with morphologically normal histology were selected. (B)  
619 Representative images from Panel 1 and Panel 2. (C) The selected fields were divided  
620 into two areas: epithelium and alveolar space. (D) Individual cells were recognized by  
621 DAPI (nuclear staining).

622 **Supplementary Figure 8. Subtyping immune and epithelial cells by multiplex**  
623 **immunofluorescence.** Cell subtypes were defined as PD-L1 expressing epithelial cells  
624 (AE1/AE3+PD-L1+), T lymphocytes (CD3+), antigen-experienced T cells (CD3+PD-1+),  
625 cytotoxic T lymphocytes (CTL, CD3+CD8+), antigen-experienced CTL (CD3+CD8+PD-  
626 1+), macrophages (CD68+) and PD-L1 expressing macrophages (CD68+PD-L1+) in  
627 panel 1 (left); and activated CTL (CD3+CD8+granzyme B+), memory T cell  
628 (CD3+CD45RO+), memory CTL (CD3+CD8+CD45RO+), regulatory T cell (CD3+CD8-  
629 FoxP3+), memory/regulatory T cell (CD3+CD45RO+FoxP3+) in panel 2 (right).

630 **Supplementary Figure 9. The correlation between immune cell subtypes measured**  
631 **by multiplex immunofluorescence and T cell subtypes inferred from immune gene**  
632 **expression.** Fractions of immune cells including CD8+ T cells (A), CD4+ T cells (B) and  
633 CD4/CD8 ratio (C) estimated using TIMER based on the gene expression from nCounter  
634 PanCancer Immune Profiling Panel (y-axis) were correlated to activated CTL  
635 (CD3+CD8+granzyme B+), regulatory T cell (CD3+CD8-FoxP3+) and Treg/activated CTL

636 ratio respectively (x-axis). All fraction and ratio were log2 transformed for visualization.

637 The correction coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

638 **Supplementary Figure 10. Various subtypes immune cells and their interaction with**  
639 **epithelial cells in normal lung tissues and invasive lung adenocarcinoma.** The  
640 correlation between immune cell subtypes and CK+ epithelial cells measured by mIF in  
641 normal lung (**A**) and invasive lung adenocarcinoma (**B**). Significant correlation was  
642 marked with \* ( $p < 0.05$ ). Red circles indicate positive correlations and blue circles indicate  
643 negative correlations. The size of circles is proportional to the spearman's correlation co-  
644 efficient between each pair of cells. ADC: Invasive adenocarcinoma.

645 **Supplementary Figure 11. Correlation between T cell diversity and regulatory T**  
646 **cells.** T cell diversity was positively correlated with infiltration of CD4+ T cells derived  
647 from immune gene expression using TIMER (**A**), regulatory T cells from multiplex  
648 immunofluorescence (mIF) (**B**). The correction coefficient ( $\rho$ ) was assessed by  
649 Spearman's rank correlation test.

650 **Supplementary Figure 12. Progressive decrease of top T cell clone frequencies**  
651 **from preneoplasia to invasive lung adenocarcinoma.** Frequencies of (**A**) top 10, (**B**)  
652 top 100, (**C**) top 200 and (**D**) top 500 T cell clones in the Normal (yellow), AAH (blue),  
653 AIS (red), MIA (green) and ADC (purple). The difference between different stages were  
654 assessed by the Kruskal-Wallis H test.

655 **Supplementary Figure 13. Correlation between T cell clonality and different T cell**  
656 **subtypes.** T cell clonality was positively correlated with infiltration of CD8+ T cells inferred  
657 from gene expression by TIMER (**A**), activated cytotoxic T cells (**B**) by mIF, expression

658 of GZBM (C) and Th1 cytokines (INFG, IL12A and IL12B) (D) but negative correlated with  
659 infiltration of CD4+ T cells derived from gene expression by TIMER (E) and regulatory T  
660 cells by mIF (F). The correction coefficient ( $\rho$ ) was assessed by Spearman's rank  
661 correlation test.

662 **Supplementary Figure 14. The impact of oncogene mutations on T cell features.**

663 Comparison of infiltration of CD8+ T cells inferred from gene expression by TIMER (A),  
664 cytotoxic T cells (CTL) (B) by mIF, CD4/CD8 ratio inferred from gene expression by  
665 TIMER (C), Effector memory cytotoxic T cells by mIF (D), CTL/Treg ratio (E) by mIF, T  
666 cell clonality by TCR sequencing (F) in lesions with *EGFR* mutation (pink), *KRAS* mutation  
667 (orange) and wildtype for both *KRAS* and *EGFR* (green). The difference was assessed  
668 by Wilcox-rank sum test.

669 **Supplementary Figure 15. The impact of oncogene mutations on T cell features by**

670 **different histologic stages.** Comparison of infiltration of CD8+ T cells inferred from gene  
671 expression by TIMER (A), cytotoxic T cells (CTL) (B) by mIF, CD4/CD8 ratio inferred from  
672 gene expression by TIMER (C), Effector memory cytotoxic T cells by mIF (D), CTL/Treg  
673 ratio (E) by mIF, T cell clonality by TCR sequencing (F) in lesions with *EGFR* mutation  
674 (pink), *KRAS* mutation (orange) and wildtype for both *KRAS* and *EGFR* (green) in AAH,  
675 AIS, MIA and ADC. The difference was assessed by Wilcox-rank sum test. AAH: Atypical  
676 adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive  
677 adenocarcinoma, ADC: Invasive adenocarcinoma.

678 **Supplementary Figure 16. Loss of heterozygosity of HLA (HLA LOH) in different**

679 **histologic stages from preneoplasia to invasive lung adenocarcinoma and its**  
680 **potential impact on immune contexture.** (A) The proportion of AAH, AIS, MIA and ADC

681 lesions had evidence of HLA-LOH. Chi-squared test were used to assess the difference  
682 among different histologic stages. The difference of infiltration of CD4+ T cells (**B**), CD8+  
683 T cells (**C**) and CD4/CD8 ratio (**D**) inferred from gene expression by TIMER between  
684 lesions with (purple) and without (green) HLA-LOH.

685 **Supplementary Figure 17. The potential impact of chromosomal copy number**  
686 **changes on immune infiltration.** The correlation between allelic imbalance (AI) burden  
687 (number of AI events) and infiltration of CD4+ T cells (**A**), CD8+ T cells (**B**), CD4/CD8  
688 ratio (**C**) inferred from gene expression by TIMER. The correlation between copy number  
689 variation (CNV) burden (normalized as the number of genes with CNV) and infiltration of  
690 CD4+ T cells (**D**), CD8+ T cells (**E**), CD4/CD8 ratio (**F**) inferred from gene expression by  
691 TIMER. The correlation coefficient ( $\rho$ ) was assessed by Spearman's rank correlation  
692 test.

693 **Supplementary Figure 18. The relationship between HLA loss and chromosomal**  
694 **copy number variations.** (**A**) Comparison of allelic imbalance (AI) burden (number of AI  
695 events) in lesions with (purple) and without (green) HLA-LOH. (**B**) Comparison of copy  
696 number variation (CNV) burden (normalized as the percent of genes with CNV) in lesions  
697 with (purple) and without (green) HLA-LOH. Willcoxon rank-sum test was used to assess  
698 the differences.

699 **Supplementary Figure 19. Impact of promoter methylation on predicted neoantigen**  
700 **burden from preneoplasia to invasive lung adenocarcinoma.** The predicted MHC  
701 Class I neoantigen ( $IC_{50} < 500nM$ ) burden (**A**) and predicted MHC Class II neoantigen  
702 ( $IC_{50} < 500nM$ ) burden (**B**) in in AAH (blue), AIS (red), MIA (green) and invasive ADC  
703 (purple). The total number of mutations associated with predicted MHC Class I



704 neoantigens (IC50 < 500nM) (**C**) and MHC Class II neoantigens (IC50 < 500nM) (**D**) in  
705 each histologic stage are shown as purple boxes. The total number of mutations  
706 associated with predicted MHC Class I neoantigens (IC50 < 500nM) (**C**) and MHC Class  
707 II neoantigens (IC50 < 500nM) (**D**) from genes without promoter methylation (<30% CpG  
708 sites methylated) are shown as blue boxes.

709 **Supplementary Figure 20. The potential impact of global methylation and immune**  
710 **infiltration.** The correlation between global methylation levels (using LINE-1 as a  
711 surrogate marker) with CD4+ T cells (**A**), CD4/CD8 ratio (**B**) inferred from immune gene  
712 expression by TIMER as well as Tregs (**C**) and Treg/CD8 ratio (**D**) measured by mIF. The  
713 correction coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

714

715 **REFERENCES**

- 716 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.*  
717 2020;70(1):7-30.
- 718 2. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, et al. Novel therapeutic  
719 targets on the horizon for lung cancer. *Lancet Oncol.* 2016;17(8):e347-e62.
- 720 3. Barnett R. Lung cancer. *Lancet.* 2017;390(10098):928.
- 721 4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab  
722 versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med.*  
723 2015;373(17):1627-39.
- 724 5. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K,  
725 Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a  
726 randomized trial. *N Engl J Med.* 2020;382(6):503-13.
- 727 6. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, et al.  
728 Overexpression of Dicer in precursor lesions of lung adenocarcinoma. *Cancer Res.*  
729 2007;67(5):2345-50.
- 730 7. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the  
731 lung: implications for the pathogenesis of peripheral lung adenocarcinoma. *Am J Clin*  
732 *Pathol.* 1999;111(5):610-22.
- 733 8. Aoyagi Y, Yokose T, Minami Y, Ochiai A, Iijima T, Morishita Y, et al. Accumulation  
734 of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma.  
735 *Cancer Res.* 2001;61(21):7950-4.
- 736 9. Noguchi M. Stepwise progression of pulmonary adenocarcinoma—clinical and  
737 molecular implications. *Cancer Metastasis Rev.* 2010;29(1):15-21.
- 738 10. Seki M, Akasaka Y. Multiple lung adenocarcinomas and AAH treated by surgical  
739 resection. *Lung Cancer.* 2007;55(2):237-40.
- 740 11. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H.  
741 Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias  
742 (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. *J Thorac Oncol.*  
743 2010;5(4):466-71.
- 744 12. Min JH, Lee HY, Lee KS, Han J, Park K, Ahn MJ, et al. Stepwise evolution from a  
745 focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma:  
746 an observation for more than 10 years. *Lung Cancer.* 2010;69(1):123-6.
- 747 13. Weichert W, Warth A. Early lung cancer with lepidic pattern: adenocarcinoma in  
748 situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. *Curr*  
749 *Opin Pulm Med.* 2014;20(4):309-16.
- 750 14. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al.  
751 International association for the study of lung cancer/american thoracic society/european  
752 respiratory society international multidisciplinary classification of lung adenocarcinoma. *J*  
753 *Thorac Oncol.* 2011;6(2):244-85.
- 754 15. Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted  
755 sequencing reveals clonal genetic changes in the progression of early lung neoplasms  
756 and paired circulating DNA. *Nat Commun.* 2015;6:8258.
- 757 16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW.  
758 Cancer genome landscapes. *Science.* 2013;339(6127):1546-58.

- 759 17. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's  
760 roles in cancer suppression and promotion. *Science*. 2011;331(6024):1565-70.
- 761 18. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, et al. Genomic  
762 landscape of atypical adenomatous hyperplasia reveals divergent modes to lung  
763 adenocarcinoma. *Cancer Res*. 2017;77(22):6119-30.
- 764 19. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, et al. Multi-region exome  
765 sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. *Nat*  
766 *Commun*. 2019;10(1):2978.
- 767 20. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis  
768 of immune signatures in longitudinal tumor samples yields insight into biomarkers of  
769 response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov*.  
770 2016;6(8):827-37.
- 771 21. Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, et al.  
772 CD47 in the tumor microenvironment limits cooperation between antitumor T-cell  
773 immunity and radiotherapy. *Cancer Res*. 2014;74(23):6771-83.
- 774 22. Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3  
775 (CD276) for human cancer immunotherapy. *Clin Cancer Res*. 2016;22(14):3425-31.
- 776 23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat*  
777 *Rev Cancer*. 2012;12(4):252-64.
- 778 24. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou J, Bensussan A.  
779 ENTPD1/CD39 is a promising therapeutic target in oncology. *Oncogene*.  
780 2013;32(14):1743-51.
- 781 25. Tschopp J, Masson D, Stanley KK. Structural/functional similarity between  
782 proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. *Nature*.  
783 1986;322(6082):831-4.
- 784 26. Prakash MD, Munoz MA, Jain R, Tong PL, Koskinen A, Regner M, et al. Granzyme  
785 B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling.  
786 *Immunity*. 2014;41(6):960-72.
- 787 27. Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D,  
788 et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral  
789 STING pathway activation in BRCA-deficient models of triple-negative breast cancer.  
790 *Cancer Discov*. 2019;9(6):722-37.
- 791 28. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat*  
792 *Rev Immunol*. 2015;15(8):486-99.
- 793 29. Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and  
794 treatment of systemic lupus erythematosus. *World J Pediatr*. 2020;16(1):19-30.
- 795 30. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-  
796 infiltrating immune cells. *Nucleic Acids Res*. 2020;49(W1):W509-14.
- 797 31. Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann  
798 JM, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. *Cell Mol*  
799 *Immunol*. 2018;15(5):458-69.
- 800 32. Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes:  
801 Implications for cancer surveillance and immunotherapy. *Oncoimmunology*.  
802 2012;1(5):717-25.
- 803 33. Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y. A reversed CD4/CD8 ratio of  
804 tumor-infiltrating lymphocytes and a high percentage of CD4+ FOXP3+ regulatory T cells


- 805 are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.  
806 *Cell Mol Immunol.* 2011;8(1):59-66.
- 807 34. Kaplinsky J, Arnaout R. Robust estimates of overall immune-repertoire diversity  
808 from high-throughput measurements on samples. *Nat Commun.* 2016;7:11881.
- 809 35. Wang X, Zhang B, Yang Y, Zhu J, Cheng S, Mao Y, et al. Characterization of  
810 distinct T cell receptor repertoires in tumor and distant non-tumor tissues from lung cancer  
811 patients. *Genomics Proteomics Bioinformatics.* 2019;17(3):287-96.
- 812 36. Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, et al. Contraction of T  
813 cell richness in lung cancer brain metastases. *Sci Rep.* 2018;8(1):2171.
- 814 37. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, et al. Comprehensive  
815 T cell repertoire characterization of non-small cell lung cancer. *Nat Commun.*  
816 2020;11(1):603.
- 817 38. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et  
818 al. Allele-specific HLA loss and immune escape in lung cancer evolution. *Cell.*  
819 2017;171(6):1259-71.e11.
- 820 39. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with  
821 markers of immune evasion and with reduced response to immunotherapy. *Science.*  
822 2017;355(6322).
- 823 40. Yarchoan M, Johnson III BA, Lutz ER, Laheru DA, Jaffee EM. Targeting  
824 neoantigens to augment antitumour immunity. *Nat Rev Cancer.* 2017;17(4):209-22.
- 825 41. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al.  
826 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint  
827 blockade. *Science.* 2016;351(6280):1463-9.
- 828 42. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, et al. The global  
829 DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter  
830 methylation and is a better prognostic factor for glioma. *PLoS One.* 2011;6(8):e23332.
- 831 43. Kankava K, Kvaratskhelia E, Burkadze G, Kokhraidze I, Gogokhia N, Abzianidze  
832 E. Line-1 methylation in blood and tissues of patients with breast cancer. *Georgian Med*  
833 *News.* 2018(276):107-12.
- 834 44. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T. Long  
835 interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage  
836 IA non-small cell lung cancer. *Clin Cancer Res.* 2010;16(8):2418-26.
- 837 45. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from  
838 immunosurveillance to tumor escape. *Nat Immunol.* 2002;3(11):991-8.
- 839 46. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer  
840 immunosurveillance and immunoediting. *Immunity.* 2004;21(2):137-48.
- 841 47. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev*  
842 *Immunol.* 2004;22:329-60.
- 843 48. O'Donnell JS, Teng MW, Smyth MJ. Cancer immunoediting and resistance to T  
844 cell-based immunotherapy. *Nat Rev Clin Oncol.* 2019;16(3):151-67.
- 845 49. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer  
846 immunoediting and its three component phases—elimination, equilibrium and escape.  
847 *Curr Opin Immunol.* 2014;27:16-25.
- 848 50. Lavin Y, Kobayashi S, Leader A, Amir E-aD, Elefant N, Bigenwald C, et al. Innate  
849 immune landscape in early lung adenocarcinoma by paired single-cell analyses.  
850 *Cell.* 2019;177(4):750-65.e17.

- 851 51. Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, et al. Immune  
852 evasion before tumour invasion in early lung squamous carcinogenesis. *Nature*.  
853 2019;571(7766):570-5.
- 854 52. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang T-HO, et al. The  
855 immune landscape of cancer. *Immunity*. 2018;48(4):812-30. e14.
- 856 53. Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture  
857 in cancer prognosis and treatment. *Nat Rev Clin Oncol*. 2017;14(12):717.
- 858 54. Liu M, Zhou J, Chen Z, Cheng AS. Understanding the epigenetic regulation of  
859 tumours and their microenvironments: opportunities and problems for epigenetic therapy.  
860 *J Pathol*. 2017;241(1):10-24.
- 861 55. Serrano A, Castro-Vega I, Redondo M. Role of gene methylation in antitumor  
862 immune response: implication for tumor progression. *Cancers (Basel)*. 2011;3(2):1672-  
863 90.
- 864 56. Bakhoun SF, Cantley LC. The multifaceted role of chromosomal instability in  
865 cancer and its microenvironment. *Cell*. 2018;174(6):1347-60.
- 866 57. Porta-Pardo E, Godzik A. Mutation drivers of immunological responses to cancer.  
867 *Cancer Immunol Res*. 2016;4(9):789-98.
- 868 58. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors  
869 promoted by DNA hypomethylation. *Science*. 2003;300(5618):455.
- 870 59. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA  
871 hypomethylation leads to elevated mutation rates. *Nature*. 1998;395(6697):89-93.
- 872 60. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, et al. DNA methylation loss  
873 promotes immune evasion of tumours with high mutation and copy number load. *Nat*  
874 *Commun*. 2019;10(1):4278.
- 875 61. Rosenthal R, Cadieux EL, Salgado R, Al Bakir M, Moore DA, Hiley CT, et al.  
876 Neoantigen-directed immune escape in lung cancer evolution. *Nature*.  
877 2019;567(7749):479-85.
- 878 62. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling  
879 of the tumor immune microenvironment. *Cell*. 2018;175(7):1972-88. e16.
- 880 63. Paulson K, Voillet V, McAfee M, Hunter D, Wagener F, Perdicchio M, et al.  
881 Acquired cancer resistance to combination immunotherapy from transcriptional loss of  
882 class I HLA. *Nature communications*. 2018;9(1):1-10.
- 883 64. Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, et al.  
884 DNA methylation-based immune response signature improves patient diagnosis in  
885 multiple cancers. *J Clin Invest*. 2017;127(8):3090-102.
- 886 65. Bellomi M, Veronesi G, Trifirò G, Brambilla S, Bonello L, Preda L, et al. Computed  
887 tomography-guided preoperative radiotracer localization of nonpalpable lung nodules.  
888 *Ann Thorac Surg*. 2010;90(6):1759-64.
- 889 66. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al.  
890 Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med*.  
891 2013;369(10):910-9.
- 892 67. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al.  
893 The RIN: an RNA integrity number for assigning integrity values to RNA measurements.  
894 *BMC Mol Biol*. 2006;7:3.
- 895 68. Cesano A. nCounter(®) PanCancer immune profiling panel (NanoString  
896 Technologies, Inc., Seattle, WA). *J Immunother Cancer*. 2015;3:42.




- 897 69. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString  
898 nCounter system. *Curr Protoc Mol Biol*. 2011;Chapter 25:Unit25B.10.
- 899 70. Pounds S, Morris SW. Estimating the occurrence of false positives and false  
900 negatives in microarray studies by approximating and partitioning the empirical  
901 distribution of p-values. *Bioinformatics*. 2003;19(10):1236-42.
- 902 71. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in  
903 Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523-30.
- 904 72. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, et al. Effect of  
905 neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung  
906 carcinomas as determined by multiplex immunofluorescence and image analysis  
907 approaches. *J Immunother Cancer*. 2018;6(1):48.
- 908 73. Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba, II. Multiplex  
909 Immunofluorescence Assays. *Methods Mol Biol*. 2020;2055:467-95.
- 910 74. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, et al. TCR repertoire  
911 intratumor heterogeneity in localized lung adenocarcinomas: an association with  
912 predicted neoantigen heterogeneity and postsurgical recurrence. *Cancer Discov*.  
913 2017;7(10):1088-97.
- 914 75. Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al.  
915 Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.  
916 *Nat Biotechnol*. 2015;33(11):1152-8.
- 917 76. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al.  
918 Allele-specific copy number analysis of tumors. *Proc Natl Acad Sci U S A*.  
919 2010;107(39):16910-5.
- 920 77. Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC  
921 class I molecules integrating information from multiple receptor and peptide length  
922 datasets. *Genome Med*. 2016;8(1):33.
- 923 78. Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M. Accurate  
924 pan-specific prediction of peptide-MHC class II binding affinity with improved binding core  
925 identification. *Immunogenetics*. 2015;67(11-12):641-50.
- 926 79. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and  
927 powerful approach to multiple testing. *J R Stat Soc B*. 1995;57(1):289-300.
- 928

# Figure 1







# Figure 2A













**Figure 2**




**Figure 3A**









**Figure 4****A****C****B**





Supplementary Figure 1



# Supplementary Figure 2


**A****CD47: p-value=0.00014****B****CD276: p-value=3.3e-14****C****CTLA4: p-value=4.1e-05****D****ENTPD1: p-value=6.3e-07****E****GZMB: p-value=5.7e-14****F****PRF1: p-value=7.9e-11**

# Supplementary Figure 3




# Supplementary Figure 4


## A




## B




## C



## D




# Supplementary Figure 5






# Supplementary Figure 6


## A



## B



# Supplementary Figure 7



A. Area selection

B. Composite image

- CK CD3 CD8
- CD68 PD-1 PD-L1
- DAPI

C. Tissue Segmentation


- Epithelium
- Alveolar space

D. Cell Segmentation


- DAPI

# Supplementary Figure 8




## Panel 1



## Panel 2




# Supplementary Figure 9

**A****B****C**




# Supplementary Figure 10



## A



## B




# Supplementary Figure 11




# Supplementary Figure 12


## A




## B









## C



## D









# Supplementary Figure 13















# Supplementary Figure 14









# Supplementary Figure 15

**A****B****C****D****E****F**

# Supplementary Figure 16


**A****B****C****D**

# Supplemental Figure S17


**A****B****C****D****E****F**

# Supplementary Figure 18

## A




## B






# Supplementary Figure 19


## A




## B






## C



## D



# Supplementary Figure 20

**A****B****C****D**